FOLH1 and metastatic prostate carcinoma: Prostate-specific membrane antigen (PSMA) TATs could be an improvement on current treatments available for patients with castration-resistant metastatic prostate cancer, and 212Pb is an advantageous choice of radionuclide due to the industrial-scale production methods available [24].